Valuation: Ardelyx, Inc.

Market Cap 982M 851M 797M 727M 1.37B 93.64B 1.39B 9.37B 3.66B 46.89B 3.69B 3.61B 156B P/E 2026 *
-21.7x
P/E 2027 * 14.1x
Enterprise Value 982M 851M 797M 727M 1.37B 93.64B 1.39B 9.37B 3.66B 46.89B 3.69B 3.61B 156B EV / Sales 2026 *
2x
EV / Sales 2027 * 1.54x
Free-Float
95.8%
Yield 2026 *
-
Yield 2027 * -
1 day+0.89%
1 week-19.14%
Current month-19.80%
1 month-22.76%
3 months-39.94%
6 months-43.37%
Current year-31.90%
1 week 3.89
Extreme 3.89
5
1 month 3.89
Extreme 3.89
5.32
Current year 3.89
Extreme 3.89
8.4
1 year 3.89
Extreme 3.89
8.4
3 years 3.16
Extreme 3.16
10.13
5 years 0.49
Extreme 0.4902
10.13
10 years 0.49
Extreme 0.4902
16.3
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2009
Director of Finance/CFO 55 04/11/2025
Chief Tech/Sci/R&D Officer 50 01/04/2026
Director TitleAgeSince
Director/Board Member 61 01/03/2009
Chairman 60 01/03/2014
Director/Board Member 59 01/03/2014
Date Insider Type Main position Quantity % Market Cap.
7/15/26 A Fiscal year

Chief Executive Officer

83,336 0.0337%
2/24/26 A Fiscal year

Chief Executive Officer

83,332 0.0343%
2/20/26 A Sell

Chief Technology Officer

3,179 0.0013%
Change 5-day change 1-year change 3-year change Capi.($)
+0.89%-19.14%-29.11%0.00% 982M
-0.73%+12.52%+74.33%+102.34% 70.51B
+1.60%+1.66%+37.76%+66.48% 54.05B
+0.42%+34.86%+9.45%+498.81% 28.95B
-0.61%+12.95%+53.77%+5.42% 24.05B
+0.45%+0.95%-16.17%-13.39% 23.31B
-1.37%+18.52%+255.24%+464.53% 18.67B
+2.21%+7.66%+47.18%-19.64% 18.37B
0.00%+9.69%+31.01%+584.59% 16.1B
-0.19%-9.42%+35.34%+138.77% 12.72B
Average +0.27%+6.15%+49.88%+182.79% 26.77B
Weighted average by Cap. +0.21%+10.00%+56.12%+166.44%

Financials

2026 *2027 *
Net sales 490M 424M 398M 363M 682M 46.71B 692M 4.68B 1.83B 23.39B 1.84B 1.8B 77.98B 638M 553M 518M 473M 889M 60.89B 902M 6.09B 2.38B 30.49B 2.4B 2.34B 102B
Net income -45.34M -39.28M -36.8M -33.57M -63.11M -4.32B -64.08M -433M -169M -2.17B -170M -167M -7.22B 61.07M 52.91M 49.58M 45.22M 85.01M 5.82B 86.32M 583M 228M 2.92B 229M 224M 9.73B
Net Debt - -
Logo Ardelyx, Inc.
Ardelyx, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It is also developing a next-generation NHE3 inhibitor, RDX10531, which has demonstrated in preclinical models to have improved solubility and potency compared to tenapanor. RDX10531 has applications across multiple therapeutic areas.
Employees
489
Date Price Change Volume
12/08/26 $3.975 +0.89% 2,020,323
11/08/26 $3.940 -1.50% 8,166,587
10/08/26 $4.000 0.00% 10,814,226
07/08/26 $4.000 -17.86% 20,071,166
06/08/26 $4.870 -0.81% 7,283,060
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
3.940USD
Average target price
13.00USD
Spread / Average Target
+229.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARDX Stock